The cell and gene therapy space in recent months has hit several speedbumps, including layoffs, dropped drugs and ...

Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell therapy delivered via an implantable device, after clinical trial data showed the treatment did not ...